{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-26-000061","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2026-08-11T11:40:55+00:00","discovered_at":"2026-08-11T11:45:00.415966+00:00","generated_at":"2026-08-11T11:45:11.072009+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Intensity Q2 2026 net loss $3.0M; resumes sarcoma and TNBC trials","bullets":["Q2 2026 net loss $3.0M vs $2.5M in Q2 2025; R&D $1.8M, G&A $1.3M.","Cash $9.5M at June 30; raised $1.6M net from ATM in Q2, $1.3M more after quarter end.","Phase 3 INVINCIBLE-3 resumed enrollment activities in April 2026 after FDA-reviewed protocol amendment; 21 patients previously enrolled.","Phase 2 INVINCIBLE-4 restarted treatment in July 2026; preliminary pCR 71% vs 42% for SOC; full enrollment targeted by end 2027.","Opened first France site for INVINCIBLE-4; increased business development activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-26-000061","json":"https://secwatch.observer/filing/0001567264-26-000061.json","markdown":"https://secwatch.observer/filing/0001567264-26-000061.md","text":"https://secwatch.observer/filing/0001567264-26-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000061/0001567264-26-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000061/intensity-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:45:11.072009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}